Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
3.000
+0.180 (+6.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
June 15, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Editas Medicine Announces Pricing of Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
What 6 Analyst Ratings Have To Say About Editas Medicine
↗
June 13, 2023
Via
Benzinga
Editas Medicine's Return On Capital Employed Insights
↗
May 19, 2023
Via
Benzinga
6 Analysts Have This to Say About Editas Medicine
↗
May 08, 2023
Via
Benzinga
Editas Medicine: Q1 Earnings Insights
↗
May 05, 2023
Via
Benzinga
Preview: Editas Medicine's Earnings
↗
May 04, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
↗
June 13, 2023
Via
Benzinga
5 Stocks to Buy With Explosive 500% Potential
↗
June 12, 2023
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential.
Via
InvestorPlace
Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
↗
June 09, 2023
Editas Medicine Inc (NASDAQ: EDIT) annou
Via
Benzinga
2 Stocks Under $15 Per Share to Consider
↗
April 16, 2023
Anyone can get in on the stock market at these prices.
Via
The Motley Fool
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
June 09, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
↗
June 06, 2023
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.
Via
InvestorPlace
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
June 06, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
↗
June 01, 2023
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that...
Via
Benzinga
7 Short-Squeeze Stocks Set for a May Rally
↗
May 22, 2023
While targeting the best short-squeeze stocks to buy now can be incredibly treacherous, they may also yield robust returns.
Via
InvestorPlace
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
↗
May 21, 2023
It's facing a few issues that are practically guaranteed to affect shareholder returns.
Via
The Motley Fool
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
May 18, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
May 16, 2023
Michelle Robertson to remain with Company until August 16, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
May 15, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
May 11, 2023
Company-sponsored webinar to be announced
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results and Business Updates
May 05, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
May 01, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 5, 2023
↗
May 05, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
Via
Benzinga
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
May 01, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
The 3 Most Promising Gene Editing Stocks to Buy in 2023
↗
April 28, 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.
Via
InvestorPlace
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
April 27, 2023
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end
From
Editas Medicine, Inc.
Via
GlobeNewswire
Why Shares of Editas Medicine Rose Monday
↗
April 17, 2023
The company is benefiting from positive news affecting other gene-editing stocks.
Via
The Motley Fool
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
